Prostate Cancer
Conditions
Keywords
prostate cancer, radiotherapy, hypofraction, radiosensitivity, image-guidance
Brief summary
This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.
Detailed description
This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.
Interventions
PROCEDUREradiotherapy
Sponsors
Calgary Health Region
Alberta Health services
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Stage T1 and T2 prostate cancer * Prostate specific antigen (PSA)\>=20 and Gleason score\<=6 * PSA\<=15 and Gleason score 7 * Signed informed consent
Exclusion criteria
* No hip prosthesis, pins or screws * No previous pelvic radiotherapy * No inflammatory bowel disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rectal morbidity | — |
Countries
Canada
Outcome results
None listed